strong > Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP & trade; biomarker for Mundipharma EDO & rsquo;s lead compound EDO-S101 for the treatment of cancer. < /strong > < /p > < p class="stdBody" > < b style="line-height: 1..."> < strong > Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP & trade; biomarker for Mundipharma EDO & rsquo;s lead compound EDO-S101 for the treatment of cancer. < /strong > < /p > < p class="stdBody" > < b style="line-height: 1..." /> < strong > Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP & trade; biomarker for Mundipharma EDO & rsquo;s lead compound EDO-S101 for the treatment of cancer. < /strong > < /p > < p class="stdBody" > < b style="line-height: 1..." />